Submitted by Anonymous (not verified) on 1 December 2023 - 15:10
Human medicines European public assessment report (EPAR): Ogivri, trastuzumab, Stomach Neoplasms;Breast Neoplasms, Date of authorisation: 12/12/2018, Revision: 11, Status: Authorised
Source: